BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38594748)

  • 1. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
    Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
    J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Role of p60AmotL2 in Epithelial Extrusion and Cell Detachment.
    Cui W; Subramani A; Fonseca P; Zhang Y; Tong L; Zhang Y; Egevad L; Lundqvist A; Holmgren L
    Cells; 2023 Aug; 12(17):. PubMed ID: 37681890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of E-Cadherin Function through the AmotL2 Isoforms Promotes Ameboid Cell Invasion.
    Subramani A; Cui W; Zhang Y; Friman T; Zhao Z; Huang W; Fonseca P; Lui WO; Narayanan V; Bobrowska J; Lekka M; Yan J; Conway DE; Holmgren L
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.
    Druzhyna N; Szczesny B; Olah G; Módis K; Asimakopoulou A; Pavlidou A; Szoleczky P; Gerö D; Yanagi K; Törö G; López-García I; Myrianthopoulos V; Mikros E; Zatarain JR; Chao C; Papapetropoulos A; Hellmich MR; Szabo C
    Pharmacol Res; 2016 Nov; 113(Pt A):18-37. PubMed ID: 27521834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
    Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
    Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 8. [Identification of a new pro-invasion factor in tumor microenvironment: progress in function and mechanism of extracellular ATP].
    Fang WG; Tian XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):188-195. PubMed ID: 28416823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
    Mertens S; Huismans MA; Verissimo CS; Ponsioen B; Overmeer R; Proost N; van Tellingen O; van de Ven M; Begthel H; Boj SF; Clevers H; Roodhart JML; Bos JL; Snippert HJG
    Cell Rep; 2023 Apr; 42(4):112324. PubMed ID: 37000626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydropeptidase 1 promotes metastasis through regulation of E-cadherin expression in colon cancer.
    Park SY; Lee SJ; Cho HJ; Kim TW; Kim JT; Kim JW; Lee CH; Kim BY; Yeom YI; Lim JS; Lee Y; Lee HG
    Oncotarget; 2016 Feb; 7(8):9501-12. PubMed ID: 26824987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
    Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
    Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.
    Paschall AV; Zimmerman MA; Torres CM; Yang D; Chen MR; Li X; Bieberich E; Bai A; Bielawski J; Bielawska A; Liu K
    BMC Cancer; 2014 Jan; 14():24. PubMed ID: 24422988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET bromodomain is a novel regulator of TAZ and its activity.
    Duan Q; Xiao Y; Zhu L; Liu Z; Mao X; Zhou Z; Liao C; Cai J; Huang F; Liu Z; Zeng J; Xia K; Chang C; Qi J; Chen Z; Huang H; Yang T
    Biochim Biophys Acta; 2016 Dec; 1859(12):1527-1537. PubMed ID: 27717711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. lincRNA-p21 Mediates the Anti-Cancer Effect of Ginkgo Biloba Extract EGb 761 by Stabilizing E-Cadherin Protein in Colon Cancer.
    Chang L; Liu T; Chai Z; Jie S; Li Z; Liu M; Dong W; Wang X; Zhou B
    Med Sci Monit; 2018 Dec; 24():9488-9496. PubMed ID: 30594943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer.
    Küçükköse E; Laoukili J; Gorelick AN; Degner S; Laclé MM; van den Bent L; Peters NA; Verheem A; Hung WT; Frenkel NC; Wassenaar ECE; Lansu N; Lenos KJ; Vermeulen L; Koopman M; Roodhart JML; Kops GJPL; Borel Rinkes IHM; Hagendoorn J; Naxerova K; Kranenburg O
    Gastroenterology; 2023 Aug; 165(2):429-444.e15. PubMed ID: 36906044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.